Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALOG's Cash to Debt is ranked higher than
97% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.19 vs. ALOG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ALOG' s Cash to Debt Range Over the Past 10 Years
Min: 1.32  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.82
ALOG's Equity to Asset is ranked higher than
83% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. ALOG: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
ALOG' s Equity to Asset Range Over the Past 10 Years
Min: 0.71  Med: 0.83 Max: 0.88
Current: 0.82
0.71
0.88
Interest Coverage No Debt
ALOG's Interest Coverage is ranked higher than
96% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.98 vs. ALOG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ALOG' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 6
Z-Score: 7.42
M-Score: -2.74
WACC vs ROIC
7.14%
5.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.11
ALOG's Operating margin (%) is ranked higher than
57% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. ALOG: 5.11 )
Ranked among companies with meaningful Operating margin (%) only.
ALOG' s Operating margin (%) Range Over the Past 10 Years
Min: -1.49  Med: 5.29 Max: 8.24
Current: 5.11
-1.49
8.24
Net-margin (%) 2.71
ALOG's Net-margin (%) is ranked higher than
55% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.03 vs. ALOG: 2.71 )
Ranked among companies with meaningful Net-margin (%) only.
ALOG' s Net-margin (%) Range Over the Past 10 Years
Min: 0.94  Med: 5.67 Max: 8.34
Current: 2.71
0.94
8.34
ROE (%) 2.70
ALOG's ROE (%) is ranked higher than
56% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.56 vs. ALOG: 2.70 )
Ranked among companies with meaningful ROE (%) only.
ALOG' s ROE (%) Range Over the Past 10 Years
Min: 0.9  Med: 5.88 Max: 9.9
Current: 2.7
0.9
9.9
ROA (%) 2.25
ALOG's ROA (%) is ranked higher than
61% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. ALOG: 2.25 )
Ranked among companies with meaningful ROA (%) only.
ALOG' s ROA (%) Range Over the Past 10 Years
Min: 0.76  Med: 4.97 Max: 7.98
Current: 2.25
0.76
7.98
ROC (Joel Greenblatt) (%) 9.06
ALOG's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. ALOG: 9.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALOG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2.21  Med: 11.01 Max: 18.74
Current: 9.06
-2.21
18.74
Revenue Growth (3Y)(%) 1.40
ALOG's Revenue Growth (3Y)(%) is ranked lower than
58% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. ALOG: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALOG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.3  Med: 5.10 Max: 15.7
Current: 1.4
-10.3
15.7
EBITDA Growth (3Y)(%) 3.40
ALOG's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ALOG: 3.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALOG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.3  Med: 0.80 Max: 62.7
Current: 3.4
-41.3
62.7
EPS Growth (3Y)(%) -8.10
ALOG's EPS Growth (3Y)(%) is ranked lower than
60% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. ALOG: -8.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALOG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.3  Med: -4.70 Max: 128.8
Current: -8.1
-55.3
128.8
» ALOG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-09-16)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ALOG Guru Trades in Q2 2015

Paul Tudor Jones 8,700 sh (+141.67%)
Richard Snow 136,390 sh (+69.76%)
NWQ Managers 552,722 sh (+4.19%)
Chuck Royce 539,395 sh (-6.44%)
» More
Q3 2015

ALOG Guru Trades in Q3 2015

Mariko Gordon 531,690 sh (New)
Jim Simons 9,554 sh (New)
Richard Snow 158,244 sh (+16.02%)
Chuck Royce 541,645 sh (+0.42%)
Paul Tudor Jones Sold Out
NWQ Managers 480,742 sh (-13.02%)
» More
Q4 2015

ALOG Guru Trades in Q4 2015

Jim Simons 21,754 sh (+127.70%)
Richard Snow 184,779 sh (+16.77%)
NWQ Managers 508,722 sh (+5.82%)
Mariko Gordon 557,904 sh (+4.93%)
Chuck Royce 542,745 sh (+0.20%)
» More
Q1 2016

ALOG Guru Trades in Q1 2016

Joel Greenblatt 35,680 sh (New)
NWQ Managers 544,777 sh (+7.09%)
Chuck Royce 565,701 sh (+4.23%)
Mariko Gordon 578,814 sh (+3.75%)
Jim Simons 19,800 sh (-8.98%)
Richard Snow 139,590 sh (-24.46%)
» More
» Details

Insider Trades

Latest Guru Trades with ALOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:ABAX, NAS:AFFX, NAS:EXAS, NAS:GHDX, NAS:VIVO, NAS:AXDX, NAS:KANG, NAS:NTRA, NAS:FMI, NAS:NEO, OTCPK:EPLYF, NAS:NVDQ, NAS:QDEL, NAS:BEAT, NAS:NRCIA, AMEX:SENS, AMEX:ONVO, NAS:SRDX, NYSE:NVTA, NAS:FLDM » details
Traded in other countries:AJM.Germany,
Analogic Corp is a technology company that designs and manufactures medical imaging ultrasound and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users in the healthcare and airport security markets.

Analogic Corporation was incorporated in the Commonwealth of Massachusetts in November 1967. The company is a technology company that designs and manufactures medical imaging and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users mainly in the healthcare and airport security markets. The Company's operating segments are Ultrasound, Medical Imaging, and Security and Detection. The Ultrasound segment provides ultrasound guidance systems for the urology and surgery markets and is expanding into point of care areas such as anesthesia and emergency medicine. The Medical Imaging segment provides critical enabling medical imaging systems and subsystems for computed tomography, or CT, magnetic resonance imaging, or MRI and high-resolution digital mammography systems. The Security and Detection segment designs and manufactures automated threat detection systems for aviation baggage inspection applications utilizing CT technology. Its geographical areas include United states, Japan, Germany, Netherlands and others.

Ratios

vs
industry
vs
history
P/E(ttm) 71.35
ALOG's P/E(ttm) is ranked lower than
90% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.99 vs. ALOG: 71.35 )
Ranked among companies with meaningful P/E(ttm) only.
ALOG' s P/E(ttm) Range Over the Past 10 Years
Min: 10.78  Med: 32.23 Max: 150.52
Current: 71.35
10.78
150.52
Forward P/E 17.24
ALOG's Forward P/E is ranked higher than
69% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.76 vs. ALOG: 17.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 71.35
ALOG's PE(NRI) is ranked lower than
91% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.19 vs. ALOG: 71.35 )
Ranked among companies with meaningful PE(NRI) only.
ALOG' s PE(NRI) Range Over the Past 10 Years
Min: 15.03  Med: 33.31 Max: 172.94
Current: 71.35
15.03
172.94
Price/Owner Earnings (ttm) 7.36
ALOG's Price/Owner Earnings (ttm) is ranked higher than
95% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.99 vs. ALOG: 7.36 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALOG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.82  Med: 43.01 Max: 839.04
Current: 7.36
6.82
839.04
P/B 1.89
ALOG's P/B is ranked higher than
74% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.23 vs. ALOG: 1.89 )
Ranked among companies with meaningful P/B only.
ALOG' s P/B Range Over the Past 10 Years
Min: 0.82  Med: 1.80 Max: 2.53
Current: 1.89
0.82
2.53
P/S 1.93
ALOG's P/S is ranked higher than
67% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ALOG: 1.93 )
Ranked among companies with meaningful P/S only.
ALOG' s P/S Range Over the Past 10 Years
Min: 0.78  Med: 1.82 Max: 3.09
Current: 1.93
0.78
3.09
PFCF 28.94
ALOG's PFCF is ranked lower than
53% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.66 vs. ALOG: 28.94 )
Ranked among companies with meaningful PFCF only.
ALOG' s PFCF Range Over the Past 10 Years
Min: 13.87  Med: 33.32 Max: 169.1
Current: 28.94
13.87
169.1
POCF 21.35
ALOG's POCF is ranked lower than
61% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.46 vs. ALOG: 21.35 )
Ranked among companies with meaningful POCF only.
ALOG' s POCF Range Over the Past 10 Years
Min: 9.02  Med: 21.53 Max: 81.55
Current: 21.35
9.02
81.55
EV-to-EBIT 32.42
ALOG's EV-to-EBIT is ranked lower than
77% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.18 vs. ALOG: 32.42 )
Ranked among companies with meaningful EV-to-EBIT only.
ALOG' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.6  Med: 25.10 Max: 388.6
Current: 32.42
-121.6
388.6
EV-to-EBITDA 17.43
ALOG's EV-to-EBITDA is ranked lower than
65% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.58 vs. ALOG: 17.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALOG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.9  Med: 15.20 Max: 48.4
Current: 17.43
5.9
48.4
PEG 6.92
ALOG's PEG is ranked lower than
90% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. ALOG: 6.92 )
Ranked among companies with meaningful PEG only.
ALOG' s PEG Range Over the Past 10 Years
Min: 0.8  Med: 2.39 Max: 345.88
Current: 6.92
0.8
345.88
Shiller P/E 44.38
ALOG's Shiller P/E is ranked lower than
60% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. ALOG: 44.38 )
Ranked among companies with meaningful Shiller P/E only.
ALOG' s Shiller P/E Range Over the Past 10 Years
Min: 15.53  Med: 34.87 Max: 53.38
Current: 44.38
15.53
53.38
Current Ratio 4.30
ALOG's Current Ratio is ranked higher than
70% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.85 vs. ALOG: 4.30 )
Ranked among companies with meaningful Current Ratio only.
ALOG' s Current Ratio Range Over the Past 10 Years
Min: 2.82  Med: 5.06 Max: 7.99
Current: 4.3
2.82
7.99
Quick Ratio 2.65
ALOG's Quick Ratio is ranked higher than
54% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ALOG: 2.65 )
Ranked among companies with meaningful Quick Ratio only.
ALOG' s Quick Ratio Range Over the Past 10 Years
Min: 2.13  Med: 3.78 Max: 6.15
Current: 2.65
2.13
6.15
Days Inventory 178.64
ALOG's Days Inventory is ranked lower than
78% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.32 vs. ALOG: 178.64 )
Ranked among companies with meaningful Days Inventory only.
ALOG' s Days Inventory Range Over the Past 10 Years
Min: 92.53  Med: 113.21 Max: 151.19
Current: 178.64
92.53
151.19
Days Sales Outstanding 66.25
ALOG's Days Sales Outstanding is ranked lower than
56% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. ALOG: 66.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALOG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.12  Med: 65.93 Max: 80.6
Current: 66.25
54.12
80.6
Days Payable 40.73
ALOG's Days Payable is ranked lower than
61% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. ALOG: 40.73 )
Ranked among companies with meaningful Days Payable only.
ALOG' s Days Payable Range Over the Past 10 Years
Min: 27.53  Med: 35.65 Max: 45.64
Current: 40.73
27.53
45.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
ALOG's Dividend Yield is ranked lower than
83% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.25 vs. ALOG: 0.50 )
Ranked among companies with meaningful Dividend Yield only.
ALOG' s Dividend Yield Range Over the Past 10 Years
Min: 0.41  Med: 0.63 Max: 1.6
Current: 0.5
0.41
1.6
Dividend Payout 0.35
ALOG's Dividend Payout is ranked higher than
62% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. ALOG: 0.35 )
Ranked among companies with meaningful Dividend Payout only.
ALOG' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.19 Max: 5
Current: 0.35
0.04
5
Forward Dividend Yield 0.50
ALOG's Forward Dividend Yield is ranked lower than
86% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.25 vs. ALOG: 0.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.50
ALOG's Yield on cost (5-Year) is ranked lower than
85% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. ALOG: 0.50 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALOG' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.41  Med: 0.63 Max: 1.6
Current: 0.5
0.41
1.6
3-Year Average Share Buyback Ratio -0.70
ALOG's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.00 vs. ALOG: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALOG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.6  Med: -0.60 Max: 2.8
Current: -0.7
-1.6
2.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 94.85
ALOG's Price/Net Cash is ranked lower than
91% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.35 vs. ALOG: 94.85 )
Ranked among companies with meaningful Price/Net Cash only.
ALOG' s Price/Net Cash Range Over the Past 10 Years
Min: 3.17  Med: 7.84 Max: 148.14
Current: 94.85
3.17
148.14
Price/Net Current Asset Value 3.53
ALOG's Price/Net Current Asset Value is ranked higher than
77% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.70 vs. ALOG: 3.53 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALOG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.28  Med: 2.56 Max: 4.77
Current: 3.53
1.28
4.77
Price/Tangible Book 2.45
ALOG's Price/Tangible Book is ranked higher than
75% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.69 vs. ALOG: 2.45 )
Ranked among companies with meaningful Price/Tangible Book only.
ALOG' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.93  Med: 1.90 Max: 3.17
Current: 2.45
0.93
3.17
Price/Projected FCF 1.52
ALOG's Price/Projected FCF is ranked higher than
67% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. ALOG: 1.52 )
Ranked among companies with meaningful Price/Projected FCF only.
ALOG' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.40 Max: 2.06
Current: 1.52
0.8
2.06
Price/Median PS Value 1.06
ALOG's Price/Median PS Value is ranked lower than
62% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. ALOG: 1.06 )
Ranked among companies with meaningful Price/Median PS Value only.
ALOG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 0.97 Max: 1.55
Current: 1.06
0.43
1.55
Price/Peter Lynch Fair Value 13.04
ALOG's Price/Peter Lynch Fair Value is ranked lower than
100% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. ALOG: 13.04 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALOG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.82  Med: 2.44 Max: 14.54
Current: 13.04
0.82
14.54
Price/Graham Number 2.79
ALOG's Price/Graham Number is ranked higher than
55% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.18 vs. ALOG: 2.79 )
Ranked among companies with meaningful Price/Graham Number only.
ALOG' s Price/Graham Number Range Over the Past 10 Years
Min: 1  Med: 1.64 Max: 11.2
Current: 2.79
1
11.2
Earnings Yield (Greenblatt) (%) 3.10
ALOG's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. ALOG: 3.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALOG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 3.90 Max: 8.3
Current: 3.1
0.3
8.3
Forward Rate of Return (Yacktman) (%) 8.41
ALOG's Forward Rate of Return (Yacktman) (%) is ranked lower than
53% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.84 vs. ALOG: 8.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALOG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -20.7  Med: 5.40 Max: 33.9
Current: 8.41
-20.7
33.9

More Statistics

Revenue (TTM) (Mil) $525.3
EPS (TTM) $ 1.13
Beta0.72
Short Percentage of Float7.41%
52-Week Range $68.71 - 90.70
Shares Outstanding (Mil)12.38

Analyst Estimate

Jul16 Jul17 Jul18
Revenue (Mil $) 509 541 585
EPS ($) 3.62 4.68 5.73
EPS w/o NRI ($) 3.62 4.68 5.73
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:ALOG

Headlines

Articles On GuruFocus.com
Mariko Gordon Sells Stake in Dealertrack Technologies Dec 02 2015 
Mariko Gordon Uses Her Magic Touch and Acquires Holdings in Two Companies Nov 23 2015 
Could These Science Stocks Provide Big Gains? Mar 11 2012 
Weekly Top Insider Buys: Health Care REIT Inc., Human Genome Sciences Inc., Conseco Inc., Universal Jan 02 2010 
Analogic Corp. Reports Operating Results (10-K) Sep 29 2009 
Analogic Corp. (ALOG) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
The Morning Risk Report: Analogic Settlement Offers Clues on New Policies Jun 23 2016
Analogic Settles Distributor Inquiry Jun 22 2016
SEC Issues FCPA Charges Against Medical Device Manufacturer Jun 22 2016
Analogic Resolves Distributor Inquiry Jun 22 2016
ANALOGIC CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 22 2016
Analogic Resolves Distributor Inquiry Jun 22 2016
​Foreign subsidiary of Analogic to pay $14M to settle bribery charges Jun 22 2016
Analogic, BK Medical agree to pay $15M to settle charges Jun 21 2016
Analogic, BK Medical agree to pay $15M to settle charges Jun 21 2016
Medical Device Company Settles Foreign Bribery Charges Jun 21 2016
ANALOGIC CORP Financials Jun 08 2016
ANALOGIC CORP Files SEC form 10-Q, Quarterly Report Jun 02 2016
Edited Transcript of ALOG earnings conference call or presentation 1-Jun-16 9:00pm GMT Jun 02 2016
Analogic Announces Results for the Third Quarter Ended April 30, 2016 and Declares Quarterly Cash... Jun 01 2016
Analogic posts 3Q profit Jun 01 2016
Analogic posts 3Q profit Jun 01 2016
ANALOGIC CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jun 01 2016
Analogic Announces Results for the Third Quarter Ended April 30, 2016 and Declares Quarterly Cash... Jun 01 2016
Q3 2016 Analogic Corp Earnings Release - After Market Close Jun 01 2016
Analogic to Present at Jefferies 2016 Healthcare Conference May 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)